The U.S. War Department is supporting the development of ketamine tablets that dissolve under the tongue to treat wounded soldiers on the battlefield, with manufacturer iX Biopharma pursuing emergency approval for military use before full FDA approval. ■ According to defense reports Oct. 22, the Pentagon awarded Singapore-based iX Biopharma A $40.95 million in contracts in February to develop Wafermine, a ketamine-based pain reliever designed to treat In moderate to serious injuries without shots. On September 3, the US government issued a declaration of emergency use following Secretary of War Pete Heath's determination that US forces were facing a significant military emergency.

The U.S. War Department is supporting the development of ketamine tablets that dissolve under the tongue to treat wounded soldiers on the battlefield, with manufacturer iX Biopharma pursuing emergency approval for military use before full FDA approval. ■ According to defense reports Oct. 22, the Pentagon awarded Singapore-based iX Biopharma A $40.95 million in contracts in February to develop Wafermine, a ketamine-based pain reliever designed to treat In moderate to serious injuries without shots. On September 3, the US government issued a declaration of emergency use following Secretary of War Pete Heath's determination that US forces were facing a significant military emergency.